Home » Newsletters » BioWorld Science

BioWorld Science

April 8, 2016

View Archived Issues

Bayer Schering Pharma divulges factor XIa inhibitors

Changzhou Yinsheng Pharmaceutical and Sichuan University patent HCV NS4B inhibitors

Jiangsu Carefree, Nanjing Carephar and Nanjing Carephar Shenghui report JAK inhibitors

Intra-Cellular Therapies discloses PDE1B inhibitors

FORMA Therapeutics introduces isocitrate dehydrogenase inhibitors

UChicago and Evelo Biosciences sign agreement to develop cancer therapy

Ironwood reports first-in-human results for cardiovascular disease candidate IW-1973

FDA accepts IND application for Adaptimmune affinity enhanced T-cell therapy targeting AFP

Immunovaccine and Leidos to collaborate on a Zika virus vaccine candidate

Pfizer and IBM to develop remote monitoring system for Parkinson's disease patients

Juno Therapeutics and Wuxi AppTec start new cell therapy-focused company in China

Galapagos begins phase IIa study of GLPG-1690 in IPF

New biomarker panel described for Hirschprung disease

S100-A4 overexpression shows promise as a prognostic biomarker for signet-ring cell carcinoma

Cynata Therapeutics's MSC product shows promising results in murine model of GvHD

Two of Volition Rx's blood-based biomarker assays receive CE Mark

Large, multinational studies of anti-HIV antibody VRC-01 launched by NIH

E.U. approves subcutaneous formulation of epoetin alfa product Binocrit for nephrology use

Cardiac MyBP-C is a highly senstitive biomarker of myocardial injury

FDA places clinical hold on IONIS-TTRRx study

IMT-001, an immunotherapy for the treatment of early-onset type 1 diabetes

AstraZeneca and Lilly announce continuation of pivotal Alzheimer's disease trial

FDA committee recommends accelerated approval of Ocaliva

DURECT announces changes in phase III trial PERSIST

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...
Seed funding at Adjuvia to treat mitochondrial dysfunction
BioWorld Science
Adjuvia Therapeutics Inc. has closed a $8 million series seed financing round to advance its work developing therapeutics to treat mitochondrial dysfunction and...
Replimune’s RP-1 for melanoma wins over FDA adcom
BioWorld
Following two complete response letters in the past year, Replimune Group Inc.’s RP-1 (suvolimogene oderparepvec) for unresectable metastatic cutaneous melanoma...